Tirzepatide effectiveness and safety for diabetes and weight loss in Paraguay
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests how well and safely tirzepatide (a new injectable medication) works in real-world conditions for people with type 2 diabetes or obesity in Paraguay. The medication helps lower blood sugar and reduce weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–70 years old and have lived in Paraguay for at least 12 months
- You speak Spanish well enough to complete study forms and follow instructions
- You have not been hospitalized for diabetes or weight-related complications in the past 3 months
- Your kidneys work adequately (eGFR ≥45 mL/min/1.73m²)
- You have either type 2 diabetes (HbA1c 7.0–9.5%) on stable single or dual therapy, or obesity (BMI ≥30) without diabetes and a failed diet attempt in the past year
- You have not used GLP-1 drugs (like Ozempic, Victoza) or similar medications in the past 3 months, and have never used insulin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a weekly injection called tirzepatide to help people with obesity lose weight. It will be done at Hospital de Clínicas in Paraguay and lasts about 12 months.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study tests a new medication called tirzepatide, given at carefully adjusted doses, to help people with obesity lose weight while reducing unwanted side effects. Tirzepatide is a newer injectable medicine that helps control appetite and blood sugar.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.